SQZ Biotechnologies Co Ordinary Shares SQZB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SQZB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.05
- Day Range
- $0.05–0.05
- 52-Week Range
- $0.01–0.69
- Bid/Ask
- $0.04 / $0.05
- Market Cap
- $1.37 Mil
- Volume/Avg
- 3,648 / 176,623
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.11
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 53
- Website
- https://www.sqzbiotech.com
Valuation
|
Metric
|
SQZB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.73 |
Price/Sales | 0.11 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SQZB
|
|---|---|
Quick Ratio | 1.15 |
Current Ratio | 1.37 |
Interest Coverage | — |
Quick Ratio
SQZB
Profitability
|
Metric
|
SQZB
|
|---|---|
Return on Assets (Normalized) | −66.45% |
Return on Equity (Normalized) | −142.33% |
Return on Invested Capital (Normalized) | −80.39% |
Return on Assets
SQZB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rtygpgrlng | Crlb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lfqxswm | Qppwb | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bjjyxlk | Mvfxm | $97.8 Bil | |
MRNA
| Moderna Inc | Hsvsmqjw | Lcbr | $41.3 Bil | |
ARGX
| argenx SE ADR | Gwbhsrg | Rtfk | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nbhysvhm | Phpbp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dxhfldqj | Nxslmwd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lrkpcrh | Kpdfyb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Szdlyzgghw | Jtjyhwr | $12.5 Bil | |
INCY
| Incyte Corp | Gzqxkwz | Lrbch | $11.6 Bil |